Literature DB >> 29088313

A fatal allo- and immune-mediated thrombocytopenia with a PD-L1 inhibitor.

L Leroy1, X Lafarge2, L Blouin2, F Bijou3, F Durrieu4, E Olivier5, S Le Moulec6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29088313     DOI： 10.1093/annonc/mdx693

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

Review 1.  Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review.

Authors:  Atsuto Mouri; Kyoichi Kaira; Ayako Shiono; Y U Miura; Hiroshi Kagamu
Journal:  In Vivo       Date:  2020 Mar-Apr       Impact factor: 2.155

2.  Lung adenocarcinoma initially presenting as Trousseau's syndrome treated successfully with pembrolizumab: A case report.

Authors:  Yuta Nakano; Naohiko Koide; Yoshinori Koyama; Kazuhito Nitta; Tomonobu Koizumi
Journal:  Thorac Cancer       Date:  2020-12-21       Impact factor: 3.500

3.  Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: A case report.

Authors:  Tomonori Makiguchi; Hisashi Tanaka; Kosuke Kamata; Kageaki Taima; Akira Kurose; Sadatomo Tasaka
Journal:  Thorac Cancer       Date:  2021-08-17       Impact factor: 3.500

4.  Drug-induced immune-mediated thrombocytopenia secondary to durvalumab use.

Authors:  Sean C Dougherty; Alia C Lynch; Richard D Hall
Journal:  Clin Case Rep       Date:  2021-06-22

5.  Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review.

Authors:  Nabil E Omar; Kareem A El-Fass; Abdelrahman I Abushouk; Noha Elbaghdady; Abd Elmonem M Barakat; Ahmed E Noreldin; Dina Johar; Mohamed Yassin; Anas Hamad; Shereen Elazzazy; Said Dermime
Journal:  Front Immunol       Date:  2020-10-21       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.